Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic ... Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.05 | -2.71739130435 | 1.84 | 1.99 | 1.7 | 77910 | 1.85087342 | CS |
| 4 | 0.08 | 4.6783625731 | 1.71 | 2.03 | 1.49 | 96864 | 1.77288863 | CS |
| 12 | 0.25 | 16.2337662338 | 1.54 | 3.29 | 1.22 | 3495014 | 2.46899726 | CS |
| 26 | -1.41 | -44.0625 | 3.2 | 4.08 | 1.22 | 2296751 | 2.72572626 | CS |
| 52 | -4.29 | -70.5592105263 | 6.08 | 7.92 | 1.22 | 1180387 | 2.80815142 | CS |
| 156 | -9.89 | -84.6746575342 | 11.68 | 19.93 | 1.22 | 544424 | 2.87605639 | CS |
| 260 | -9.89 | -84.6746575342 | 11.68 | 19.93 | 1.22 | 544424 | 2.87605639 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。